Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,460.59 -322.70 (-0.51%) CMC Crypto 200
1,332.63 -63.91 (-4.58%)
CERo Therapeutics Holdings, Inc. (CERO)
After hours:
| Previous close | 1.4100 |
| Open | 1.4200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.3700 - 1.4699 |
| 52-week range | 1.3300 - 12.8000 |
| Volume | |
| Avg. volume | 1,083,198 |
| Market cap | 20.171M |
| Beta (5Y monthly) | -0.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
SOUTH SAN FRANCISCO, Calif., March 07, 2024--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled "Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia." The paper details preclinical stu
- Business Wire
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
OAKLAND, Calif. & SOUTH SAN FRANCISCO, Calif., February 14, 2024--Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ("CERo") today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combinati
